Clinical trials provide clinicians with critical insight into ongoing research across a broad spectrum of health conditions. In recognition of Pancreatic Cancer Awareness Month, held every November, we highlighted several actively recruiting Phase 3 clinical trials focused on pancreatic ductal adenocarcinoma. Familiarity with current clinical trials can expand therapeutic options for patients who may otherwise lack access to investigational interventions, while also enabling clinicians to remain informed of the most current evidence-based research.

The following five pancreatic ductal adenocarcinoma clinical trials are Phase 3 trials currently recruiting in the United States.

Quick View Table of Featured Clinical Trials
Study TitlePhaseEstimated EnrollmentStart DateEstimated Primary Completion
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)2, 3470October 2025May 2029
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue2, 3982October 2025Janaury 2028
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer (LAP100)3356August 2025October 2030
The Effect of Kinisoquin on Thromboembolic Events in Patients With Metastatic Pancreatic Cancer (CATIQ P3)3480October 2025October 2027
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302)3460October 2024June 2026
Pancreatic Ductal Adenocarcinoma Phase 3, Currently Recruiting Clinical Trials Rundown

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  • Sponsor: Bristol-Myers Squibb
  • Goal: The purpose of this study is to assess the safety and efficacy of BMS-986504, a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine versus placebo in combination with nab-p/gem, in participants with untreated metastatic Pancreatic Ductal Adenocarcinoma with homozygous methylthioadenosine phosphorylase (deletion.
  • Interventions: BMS-986504, gemcitabine, nab-paclitaxel, placebo
  • Primary Outcome Measures: Progression-Free Survival as assessed by Response Evaluation Criteria in Solid Tumors version v1.1 (RECIST v1.1); Overall survival (OS).
  • Timeframe: Up to three years after last participant is randomized; Up to three years after last participant is randomized.
  • Study Details
  • Source

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  • Sponsor: Pfizer
  • Goal: Investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ductal adenocardinoma.
    Interventions: Ponsegromab, placebo.
    Primary Outcome Measures: Percent change from baseline in body weight for pnsegromab compared to placebo; Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy 5-item Anorexia Symptoms Scale scores.
  • Timeframes: Baseline, week 12; Baseline, week 12.
  • Study Details
  • Source

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer (LAP100)

  • Sponsor: NRG Oncology
  • Goal: To evaluate whether dose-escalated radiation therapy (RT) improves 3-year overall survival compared to standard treatments without dose-escalated RT, in locally advanced pancreatic cancer patients without radiographic progression and with biochemical response after an initial interval of chemotherapy.
  • Interventions: Biopsy procedure, biospecimen collection, capectibine, computed tomography, dose-escalated radiation therapy, fluorouracil, gemcitabine, irinotecan hydrochloride, irinotecan sucrosofate, leucovorin calcium, magnetic resonance imaging, nab-paclitaxel, observation activity, oxaliplatin, questionnaire administration, radiation therapy.
  • Primary Outcome Measure: Overall survival.
  • Timeframe: From randomization to the date of death or last follow-up, assessed up to three years.
  • Study Details
  • Source

The Effect of Kinisoquin on Thromboembolic Events in Patients With Metastatic Pancreatic Cancer (CATIQ P3)

  • Sponsor: Quercis Pharma AG
  • Goal: Evaluate the efficacy of Kinisoquin as compared to the placebo in prevention of thromboembolic events in patients with metastatic pancreatic cancer.
  • Interventions: Kinisoquin, placebo
  • Primary Outcome Measure: Effectiveness of Kinisoquin
  • Timeframe: 16 weeks
  • Study Details
  • Source

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302)

  • Sponsor: Revolution Medicines
  • Goal: Evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care treatment.
  • Interventions: RMC-6236, gemcitabine, nab-paclitaxel, irinotecan, liposomal irinotecan, 5-fluorouracil, leucovorin, oxaliplatin
  • Primary Outcome Measures: Progression free survival in the RAS G12-mutant population; Overall survival in the RAS G12-mutant population.
  • Timeframes: Up to approximately 3 years; up to approximately 3 years.
  • Study Details
  • Source

Sign up for alerts and stay informed on the latest published guidelines.

Copyright © 2025 Guideline Central, all rights reserved.